Safety
Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC
Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns
Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation
Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns
CAR-T therapy, durability, safety, clinical trial discontinuation, large B-cell lymphoma, firi-cel, CARGO Therapeutics
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB Pharma’s Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment
LB-102, schizophrenia, benzamide antipsychotics, Phase II trial, efficacy, safety
FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns
Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors